
|Articles|May 12, 2004
Formulation decreases risk of recurrent stone formation
Orthophosphate formula (Uro-KP-Neutral) from Star Pharmaceuticals decreasesthe risk of recurrent calcium oxalate stone formation and the growth ofresidual stones following lithotripsy. In addition, the formulation is agood source of supplemental potassium, sodium, and phosphorus, accordingto the company.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5










